HRP20140801T1 - Kratkodjelujuä†i fenilalkilaminski blokatori kalcijevih kanala i njihova uporaba - Google Patents
Kratkodjelujuä†i fenilalkilaminski blokatori kalcijevih kanala i njihova uporaba Download PDFInfo
- Publication number
- HRP20140801T1 HRP20140801T1 HRP20140801AT HRP20140801T HRP20140801T1 HR P20140801 T1 HRP20140801 T1 HR P20140801T1 HR P20140801A T HRP20140801A T HR P20140801AT HR P20140801 T HRP20140801 T HR P20140801T HR P20140801 T1 HRP20140801 T1 HR P20140801T1
- Authority
- HR
- Croatia
- Prior art keywords
- lower alkyl
- substituted
- alkoxyalkyl
- lower alkoxyalkyl
- pharmaceutical preparation
- Prior art date
Links
- 229940127291 Calcium channel antagonist Drugs 0.000 title 1
- 239000000480 calcium channel blocker Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims 32
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 23
- 239000000825 pharmaceutical preparation Substances 0.000 claims 11
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 6
- 229910052801 chlorine Chemical group 0.000 claims 6
- 239000000460 chlorine Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 229910052731 fluorine Inorganic materials 0.000 claims 6
- 239000011737 fluorine Substances 0.000 claims 6
- 125000001153 fluoro group Chemical group F* 0.000 claims 6
- 206010020772 Hypertension Diseases 0.000 claims 4
- 206010020802 Hypertensive crisis Diseases 0.000 claims 4
- 206010003119 arrhythmia Diseases 0.000 claims 4
- 230000017531 blood circulation Effects 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000000302 ischemic effect Effects 0.000 claims 4
- 230000010410 reperfusion Effects 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 238000001356 surgical procedure Methods 0.000 claims 4
- 238000007911 parenteral administration Methods 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010047302 ventricular tachycardia Diseases 0.000 claims 3
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 201000001068 Prinzmetal angina Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000007718 Stable Angina Diseases 0.000 claims 1
- 208000018452 Torsade de pointes Diseases 0.000 claims 1
- 208000002363 Torsades de Pointes Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 230000001746 atrial effect Effects 0.000 claims 1
- 206010003668 atrial tachycardia Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 230000002028 premature Effects 0.000 claims 1
- 230000034225 regulation of ventricular cardiomyocyte membrane depolarization Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/38—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to acyclic carbon atoms and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
1. Farmaceutski pripravak koji sadrži spoj sa formulom:
[image]
ili njegovu farmaceutski prihvatljivu adicijsku sol, ili bilo koji njegov enantiomer ili dijastereomer, naznačen time da
- svaki a, b, c, d, e, i f je, neovisno, -CH2-, -O-, -S-, ili jednostruka veza;
- svaki R11, R12, R13, R41, R15, R16, i R17 je, neovisno: H, niži alkil, niži alkil supstituiran s -CO2(niži alkil), niži alkil supstituiran s -CO2(niži alkoksialkil), niži alkil supstituiran s fluorom ili klorom, niži alkoksialkil, niži alkoksialkil supstituiran s -CO2(niži alkil), niži alkoksialkil supstituiran s -CO2(niži alkoksialkil), niži alkoksialkil supstituiran s fluorom ili klorom, ili CO2R10;
- svaki R10 je, neovisno, niži alkil ili niži alkoksialkil;
- R18 je H, CN, ili CO2R10; i
- R19 je H, g je jednostruka veza, i R20 je H, pri čemu
barem jedan od R11, R12, R13, R14, R15, R16, R17, i R18 je CO2R10, niži alkil supstituiran s -CO2(niži alkil), niži alkil supstituiran s -CO2(niži alkoksialkil), niži alkoksialkil supstituiran s -CO2(niži alkil), ili niži alkoksialkil supstituiran s -CO2(niži alkoksialkil); pri čemu navedeni niži alkil je C1-7 alkil i navedeni niži alkoksialkil je C1-7 alkil supstituiran s C1-7 alkoksi skupinom.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time da
(a) R17 je niži alkil;
(b) R18 je CN ili CO2R10;
(c) barem jedan od -a-R11, -b-R12, ili -c-R13 je, neovisno:
(i) -O-(niži alkil);
(ii) -O-(niži alkil supstituiran s -CO2(niži alkil));
(iii) -O-(niži alkil supstituiran s -CO2(niži alkoksialkil));
(iv) -O-(niži alkil supstituiran s fluorom ili klorom);
(v) -O-(niži alkoksialkil);
(vi) -O-(niži alkoksialkil supstituiran s -CO2(niži alkil));
(vii) -O-(niži alkoksialkil supstituiran s -CO2(niži alkoksialkil));
(viii) -O-(niži alkil supstituiran s fluorom ili klorom); ili
(ix) -(jednostruka veza)-CO2R10; i
(d) barem jedan od -d-R14, -e-R15, -f-R16, ili-g-R20 je, neovisno,
(i) -O-(niži alkil);
(ii) -O-(niži alkil supstituiran s -CO2(niži alkil));
(iii) -O-(niži alkil supstituiran s -CO2(niži alkoksialkil));
(iv) -O-(niži alkil supstituiran s fluorom ili klorom);
(v) -O-(niži alkoksialkil);
(vi) -O-(niži alkoksialkil supstituiran s -CO2(niži alkil));
(vii) -O-(niži alkoksialkil supstituiran s -CO2(niži alkoksialkil));
(viii) -O-(niži alkil supstituiran s fluorom ili klorom); ili
(ix) -(jednostruka veza)-CO2R10;
pri čemu navedeni niži alkil je C1-7 alkil i navedeni niži alkoksialkil je C1-7 alkil supstituiran s C1-7 alkoksi skupinom.
3. Farmaceutski pripravak prema zahtjevu 1, naznačen time da je navedeni spoj odabran iz skupine koju čine:
[image]
[image]
[image]
4. Farmaceutski pripravak prema zahtjevu 3, naznačen time da navedeni spoj je
[image]
5. Farmaceutski pripravak prema zahtjevu 3, naznačen time da je navedeni spoj odabran iz skupine koju čine:
[image]
i
[image]
6. Farmaceutski pripravak prema bilo kojem zahtjevu od 1-5, naznačen time da navedeni farmaceutski pripravak ima trajanje djelovanja od manje od 1 minute do manje od 60 minuta.
7. Farmaceutski pripravak prema zahtjevu 6, naznačen time da navedeni farmaceutski pripravak ima trajanje djelovanja od manje od 1 minute do manje od 30 minuta.
8. Farmaceutski pripravak prema bilo kojem zahtjevu od 1-7, naznačen time da je navedeni farmaceutski pripravak formuliran za liječenje stanja koje je odabrano iz skupine koju čine:
- ishemijska stanja srca;
- srčana aritmija;
- hipertenzivna kriza u sobi za hitne slučajeve;
- hipertenzija prije, za vrijeme, ili nakon operacije;
- fenomen odsutnosti protoka poslije reperfuzije; te
- bolest povezana sa smanjenim protokom krvi u skeletnim mišićima.
9. Komplet naznačen time da sadrži
(a) farmaceutski pripravak prema bilo kojem zahtjevu od 1-7; i
(b) instrukcija za uporabu farmaceutskog pripravka iz (a) za liječenje stanja koje je odabrano iz skupine koju čine:
- ishemijska stanja srca;
- srčana aritmija;
- hipertenzivna kriza u sobi za hitne slučajeve;
- hipertenzija prije, za vrijeme, ili nakon operacije;
- fenomen odsutnosti protoka poslije reperfuzije; te
- bolest povezana sa smanjenim protokom krvi u skeletnim mišićima.
10. Terapeutski učinkovita količina spoja prema bilo kojem zahtjevu od 1-7, ili njegova farmaceutski prihvatljiva adicijska sol, ili bilo koji njegov enantiomer ili diastereomer, ili njegov farmaceutski pripravak, naznačena time da je za uporabu kod liječenja pacijenta kojem je to potrebno:
(a) ishemijskog stanja srca, poželjno stabilna angina, nestabilna angina, ili vazospastična angina,
(b) srčana aritmija, poželjno atrijalna fibrilacija, undulacija atrija, paroksizmalna supraventrikulska tahikardija (PSVT), preuranjena atrijalna, nodalna, ili ventrikulska depolarizacija, atrijalna tahikardija, ventrikulska tahikardija, ventrikulska fibrilacija, ili Torsades de Pointes,
(c) hipertenzivna kriza u sobi za hitne slučajeve,
(d) hipertenzija prije, za vrijeme, ili nakon operacije,
(e) fenomen odsutnosti protoka poslije reperfuzije,
(f) bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, poželjno Raynaudov fenomen ili intermitentna klaudikacija,
pri čemu se navedeno liječenje sastoji od davanja spoja navedenom pacijentu.
11. Komplet prema zahtjevu 9, naznačen time da
kada je navedeno stanje ishemijsko stanje srca ili srčana aritmija, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, ili inhalacijska primjena, ili
kada je navedeno stanje hipertenzivna kriza u sobi za hitne slučajeve, navedena primjena je sublingvalna, bukalna, intranazalna, inhalacijska, ili parenteralna primjena, poželjno navedena parenteralna primjena je intravenozna primjena, ili
kada je navedeno stanje hipertenzija prije, za vrijeme, ili nakon operacije, ili fenomen odsutnosti protoka poslije reperfuzije, navedena primjena je parenteralna primjena, poželjno intravenozna primjena, ili
kada je navedeno stanje bolest povezana sa smanjenim protokom krvi u skeletnim mišićima, navedena primjena je sublingvalna, bukalna, transdermalna, intranazalna, inhalacijska, ili topikalna primjena.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93644007P | 2007-06-20 | 2007-06-20 | |
| PCT/US2008/007665 WO2008156820A1 (en) | 2007-06-20 | 2008-06-19 | Short acting phenylalkylamine calcium channel blockers and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140801T1 true HRP20140801T1 (hr) | 2014-11-21 |
Family
ID=40156562
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140801AT HRP20140801T1 (hr) | 2007-06-20 | 2014-08-22 | Kratkodjelujuä†i fenilalkilaminski blokatori kalcijevih kanala i njihova uporaba |
Country Status (19)
| Country | Link |
|---|---|
| US (16) | US20100190852A1 (hr) |
| EP (1) | EP2170050B1 (hr) |
| JP (1) | JP5421908B2 (hr) |
| KR (1) | KR101541557B1 (hr) |
| CN (1) | CN101754678B (hr) |
| AU (1) | AU2008266798B2 (hr) |
| BR (1) | BRPI0812919B8 (hr) |
| CA (1) | CA2693627C (hr) |
| CY (1) | CY1115619T1 (hr) |
| DK (1) | DK2170050T3 (hr) |
| ES (1) | ES2498047T3 (hr) |
| HK (1) | HK1140913A1 (hr) |
| HR (1) | HRP20140801T1 (hr) |
| MX (1) | MX347325B (hr) |
| NZ (1) | NZ582033A (hr) |
| PL (1) | PL2170050T3 (hr) |
| PT (1) | PT2170050E (hr) |
| SI (1) | SI2170050T1 (hr) |
| WO (1) | WO2008156820A1 (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100190852A1 (en) | 2007-06-20 | 2010-07-29 | Milestone Pharmaceuticals Inc. | Short acting phenylalkylamine calcium channel blockers and uses thereof |
| KR101052620B1 (ko) * | 2008-08-28 | 2011-07-29 | 한국과학기술연구원 | 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 |
| KR101644286B1 (ko) * | 2009-09-30 | 2016-08-10 | 마이크로도스 테라퓨특스, 인코포레이티드 | 레이노 증후군의 치료를 위한 방법들 및 조성물들 |
| WO2015073919A1 (en) * | 2013-11-14 | 2015-05-21 | University Medical Pharmaceuticals Corporation | Microneedles for therapeutic agent delivery with improved mechanical properties |
| PL3283067T3 (pl) | 2015-04-14 | 2020-09-21 | Milestone Pharmaceuticals Inc. | Wysoce rozpuszczalne w wodzie sole szybkodziałającego fenyloalkiloaminowego blokera kanałów wapniowych i ich zastosowania |
| US20230065401A1 (en) * | 2021-07-15 | 2023-03-02 | Milestone Pharmaceuticals Inc. | Methods of administration for highly water-soluble salts of a short acting phenylalkylamine calcium channel blocker |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1154810B (de) * | 1961-04-01 | 1963-09-26 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
| US3957845A (en) * | 1962-04-27 | 1976-05-18 | Knoll A.G. Chemische Fabriken | Trifluoromethyl-substituted phenyl acetonitriles |
| DE1493904A1 (de) * | 1965-07-31 | 1969-06-19 | Knoll Ag | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
| DE2059923C3 (de) * | 1970-12-05 | 1979-01-25 | Knoll Ag, 6700 Ludwigshafen | l-a-Isopropyl-o-[(N-methyl-N-homoveratryl)v-aminopropyl] -3,4-dimethoxyphenylacetonitril, Verfahren zu dessen Herstellung und dieses enthaltende Arzneimittel |
| JPS5118940B2 (hr) * | 1971-12-25 | 1976-06-14 | ||
| DE2631222C3 (de) * | 1976-07-12 | 1979-01-04 | Knoll Ag, 6700 Ludwigshafen | Verfahren zur Herstellung basisch substituierter Phenylacetonitrile |
| DE3144150A1 (de) * | 1981-04-10 | 1982-12-09 | Basf Ag, 6700 Ludwigshafen | (omega)-cyan-1,(omega)-diphenyl-azaalkan-derivate, ihre herstellung und diese enthaltende arzneimittel |
| DE3433383A1 (de) * | 1984-09-12 | 1986-03-20 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue phenyl-acetonitril-derivate |
| DE3603032A1 (de) * | 1986-01-31 | 1987-08-06 | Basf Ag | Basisch substituierte phenylacetonitrile, ihre herstellung und diese enthaltende arzneimittel |
| US4833162A (en) * | 1988-02-03 | 1989-05-23 | American Cyanamid Company | Substituted benzeneacetonitriles and their use as calcium channel blockers |
| US5162569A (en) | 1989-12-21 | 1992-11-10 | G. D. Searle & Co. | Phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
| IE64870B1 (en) | 1989-12-21 | 1995-09-20 | Searle & Co | Methods of using 2-isopropyl-2-phenylaminovaleronitriles immunosuppressants and vasodilators |
| US5486539A (en) * | 1989-12-21 | 1996-01-23 | G. D. Searle & Co. | Method of using phenylacetonitrilealkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
| US5247119A (en) * | 1990-12-12 | 1993-09-21 | G. D. Searle & Co. | Phenylacetonitrilehydroxyalkylaminoalkyl-ortho-substituted aryl compounds as immunosuppressives |
| US6057344A (en) * | 1991-11-26 | 2000-05-02 | Sepracor, Inc. | Methods for treating hypertension, and angina using optically pure (-) amlodipine |
| US5451604A (en) * | 1993-07-26 | 1995-09-19 | G. D. Searle & Co. | Halogenated phenylacetonitrile alkylaminoalkylphenyl compounds as immunosuppressives |
| US5910601A (en) * | 1994-09-26 | 1999-06-08 | Darwin Discovery Limited | Chiral nitriles, their preparation and their use for the manufacture of verapamil and analogues |
| US5859279A (en) | 1996-09-10 | 1999-01-12 | Darwin Discovery Limited | Compound and process |
| US6750238B1 (en) | 2000-05-12 | 2004-06-15 | The University Of Toledo | Aralkyl ester soft drugs |
| US7511077B2 (en) * | 2005-02-09 | 2009-03-31 | Neuromed Pharmaceuticals Ltd. | Diamine calcium channel blockers |
| GB2435824A (en) | 2006-03-09 | 2007-09-12 | Esteve Labor Dr | Use of nitrile compounds in the treatment of food related and other disorders |
| US20100190852A1 (en) | 2007-06-20 | 2010-07-29 | Milestone Pharmaceuticals Inc. | Short acting phenylalkylamine calcium channel blockers and uses thereof |
-
2008
- 2008-06-19 US US12/664,026 patent/US20100190852A1/en not_active Abandoned
- 2008-06-19 CN CN200880020979.1A patent/CN101754678B/zh active Active
- 2008-06-19 DK DK08768636.6T patent/DK2170050T3/da active
- 2008-06-19 AU AU2008266798A patent/AU2008266798B2/en active Active
- 2008-06-19 MX MX2009014052A patent/MX347325B/es active IP Right Grant
- 2008-06-19 ES ES08768636.6T patent/ES2498047T3/es active Active
- 2008-06-19 SI SI200831291T patent/SI2170050T1/sl unknown
- 2008-06-19 NZ NZ582033A patent/NZ582033A/en unknown
- 2008-06-19 EP EP08768636.6A patent/EP2170050B1/en active Active
- 2008-06-19 BR BRPI0812919A patent/BRPI0812919B8/pt active IP Right Grant
- 2008-06-19 CA CA2693627A patent/CA2693627C/en active Active
- 2008-06-19 PL PL08768636T patent/PL2170050T3/pl unknown
- 2008-06-19 PT PT87686366T patent/PT2170050E/pt unknown
- 2008-06-19 WO PCT/US2008/007665 patent/WO2008156820A1/en active Application Filing
- 2008-06-19 JP JP2010513245A patent/JP5421908B2/ja active Active
- 2008-06-19 KR KR1020107000124A patent/KR101541557B1/ko active IP Right Grant
-
2010
- 2010-08-03 HK HK10107383.8A patent/HK1140913A1/xx unknown
-
2014
- 2014-06-16 US US14/305,626 patent/US9227918B2/en active Active
- 2014-08-22 HR HRP20140801AT patent/HRP20140801T1/hr unknown
- 2014-09-18 CY CY20141100766T patent/CY1115619T1/el unknown
-
2015
- 2015-11-23 US US14/949,107 patent/US9463179B2/en active Active
-
2016
- 2016-09-12 US US15/262,567 patent/US9737503B2/en active Active
-
2017
- 2017-07-18 US US15/653,246 patent/US10010522B2/en active Active
- 2017-07-18 US US15/653,367 patent/US10010523B2/en active Active
- 2017-07-20 US US15/655,564 patent/US10010524B2/en active Active
-
2018
- 2018-06-04 US US15/997,229 patent/US20180280339A1/en not_active Abandoned
-
2019
- 2019-01-14 US US16/246,980 patent/US20190142781A1/en not_active Abandoned
- 2019-08-29 US US16/555,766 patent/US20190380993A1/en not_active Abandoned
-
2020
- 2020-04-09 US US16/844,440 patent/US20200230097A1/en not_active Abandoned
- 2020-11-12 US US17/096,498 patent/US20210059972A1/en not_active Abandoned
-
2021
- 2021-06-22 US US17/354,288 patent/US20210315855A1/en not_active Abandoned
-
2022
- 2022-01-26 US US17/584,686 patent/US20220142963A1/en not_active Abandoned
-
2023
- 2023-04-24 US US18/138,341 patent/US20230255923A1/en not_active Abandoned
- 2023-12-08 US US18/533,381 patent/US20240115543A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140801T1 (hr) | Kratkodjelujuä†i fenilalkilaminski blokatori kalcijevih kanala i njihova uporaba | |
| JP2009537246A5 (hr) | ||
| JP2009524676A5 (hr) | ||
| JP2010536761A5 (hr) | ||
| JP2010523714A5 (hr) | ||
| BRPI0413533A (pt) | derivados de malonamida que bloqueiam a atividade de gama-secretase | |
| RU2011124150A (ru) | Нафтилуксусные кислоты | |
| RU2011109084A (ru) | Терапевтические композиции, содержащие мацитентан | |
| ES2805341T3 (es) | Composiciones farmacéuticas para terapia de combinación | |
| JP2004506682A5 (hr) | ||
| JP2007506748A5 (hr) | ||
| CN101015556B (zh) | 窦房结If电流抑制剂与钙抑制剂的组合以及含有它的药物组合物 | |
| JP2008514557A5 (hr) | ||
| CH670763A5 (hr) | ||
| ATE446309T1 (de) | Den kapillarwiderstand verbessernde peptidsubstanz, darauf basierende pharmazeutische zusammensetzung und verfahren zu deren anwendung | |
| JP2002537232A5 (hr) | ||
| SG176982A1 (en) | Combination of a sodium-proton exchanger inhibitor and of a dihydro-1,3,5-triazine amine derivative | |
| DK2603486T3 (en) | Panthenyldocosahexaenoate and its use in the treatment and prevention of cardiovascular diseases | |
| JP2005533796A5 (hr) | ||
| KR20020002487A (ko) | 협심증 치료를 위한 바소펩티다제 억제제의 용도 | |
| RU2005119970A (ru) | Оптически активное производное дигидропиридина | |
| ES2483940T3 (es) | Un nuevo régimen de dosificación para compuestos moduladores del canal iónico para el tratamiento de la fibrilación auricular aguda en un ser humano | |
| JP2006520343A5 (hr) | ||
| WO2005074931A1 (en) | Pharmaceutical combinations comprising (s) -pantoprazole | |
| ES2238939B2 (es) | Citalopram para el tratamiento de la hipertension arterial. |